Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Can-Fite BioPharma ( (CANF) ) just unveiled an update.
On November 10, 2025, Can-Fite BioPharma Ltd. held a Special General Meeting of Shareholders where all proposed resolutions were approved. This approval marks a significant step for the company as it aligns with their strategic plans and could potentially impact their market positioning and stakeholder interests.
The most recent analyst rating on (CANF) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Underperform.
The overall stock score for Can-Fite BioPharma is low due to significant financial challenges, bearish technical indicators, and lack of valuation data. The company’s declining revenues, persistent losses, and reliance on external financing are major concerns. Technical analysis indicates bearish momentum, with the stock trading below key moving averages and in oversold conditions.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biopharmaceutical company based in Israel, focused on the development of small molecule drugs for the treatment of inflammatory, cancer, and liver diseases.
Average Trading Volume: 195,500
Technical Sentiment Signal: Sell
Current Market Cap: $15.7M
See more insights into CANF stock on TipRanks’ Stock Analysis page.